Uncomplicated urinary tract infection in women: Current practice and the effect of antibiotic resistance on empiric treatment

Canadian Family Physician

Volumn 52, Issue MAY, 2006, Pages 612-618

  Nicolle, Lindsay ^a,c   Anderson, Peter A M ^d   Conly, John ^d   Mainprize, Thomas C ^d   Meuser, Jamie ^d   Nickel, J Curtis ^d   Senikas, Vyta M ^d   Zhanel, George G ^b  

^a Ortho Mcneil Inc   (United States)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c HEALTH SCIENCES CENTRE   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GATIFLOXACIN; LEVOFLOXACIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; CLINICAL PRACTICE; COMMUNITY CARE; DRUG CHOICE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EDUCATION PROGRAM; EMPIRICISM; ESCHERICHIA COLI; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEALTH EDUCATION; HUMAN; MEDICAL LITERATURE; MEDLINE; NONHUMAN; PRACTICE GUIDELINE; REVIEW; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS, URINARY; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; NITROFURANTOIN; PRACTICE GUIDELINES; SULFAMETHIZOLE; TRIMETHOPRIM; URINARY TRACT INFECTIONS;

EID: 33745200064     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Hooton TM. Pathogenesis of urinary tract infections: an update. J Antimicrob Chemother 2000;46(Suppl 1):1-7.
2. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58.
3. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999;281:736-8.
4. Hooton TM, Scholes D. Hughes JP, Winter C, Roberts PL, Stapleton QE, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women, N Engl J Med 1996;335:468-74.
5. National Center for Health Statistics. National Ambulatory Medical Care Survey, United States, 1979 summary. Vital and health statistics, 13(66). Washington DC: Government Printing Office; 1982. DHHS Publication no. (PHS) 82-1727.
6. Kunin CM. Urinary tract infections in females. Clin Infect Dis 1994;18:1-12.
7. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990;80:331-3.
8. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomized, controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002;52:729-34.
9. Nicolle LE. Pivmecillinam in the treatment of urinary tract infection. J Antimicrob Chemother 2000;46(Suppl 1):35-9.
10. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;1:551-81.
11. Mazzulli T. Antimicrobial resistance trends in common urinary pathogens. Can J Urol 2001;8(Suppl 1):2-5.
12. O'Connor PJ, Solberg LI, Christianson J, Amundson G, Mosser G. Mechanism of action and impact of a cystitis clinical practice guideline on outcomes and costs of care in an HMO. Jt Comm J Qual Improv 1996;22:673-82.
13. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med 2002;113(Suppl 1A):35-44S.
14. Stamm WE. Scientific and clinical challenges in the management of urinary tract infections. Am J Med 2002;113(Suppl 1A):1-4S.
15. McCarty JM, Richard G, Huck W, Tucker RM, Tosiello RL, Shan M, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med 1999;106:292-9.
16. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999;43(Suppl A):67-75.
17. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women, JAMA 1995;273:41-5.
18. Nicolle L. Best pharmacological practice: urinary tract infections. Expert Opin Pharmacother 2003;4:693-704.
19. Saginur R, Nicolle LE. Single dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group. Arch Intern Med 1992;152:1233-7.
20. Iravani A. multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. Am J Med 1993;94(Suppl 3A):89S-96S.
21. Ode B, Walder M, Forsgren A. Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females. Scand J Infect Dis 1987;19:677-9.
22. Garlando F, Rietiker S, Tauber MG, Flepp M, Meier B, Luthy R. Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother 1987;31:354-6.
23. Gupta K. Addressing antibiotic resistance. Am J Med 2002;113(Suppl 1A):29-34S.
24. Mazzulli T, Skulnick M, Small G, Marshall W, Hoban DJ, Zhanel GG, et al. Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents. Can J Infect Dis 2001;12:289-92.
25. Zhanel GG, Karlowsky JA, Harding GK, Carrie A, Mazzulli T, Low DE, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000;44:1089-92.
26. Kahlmeter G. The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens - interim report. J Antimicrob Chemother 2000;46(Suppl 1):15-22.
27. The Surveillance Network (TSN) Database. TSNR Database - USA, 2002. Cypress, Calif and Herndon, Va: Focus Technologies, Inc; 2002. Available at: http://www.utizone.ca. Accessed 2006 February 21.
28. McIsaac WJ, Mazzulli T, Moineddin R, Raboud J, Ross S. Uropathogen antibiotic resistance in adult women presenting to family physicians with acute uncomplicated cystitis. Can J Infect Dis Med Microbiol 2004;15:266-70.
29. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001;135:41-50.
30. Zhanel GG, Hisanaga TL, Laing NM, Decorby MR, Nichol KA, Palatnick LP, et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2005;26:380-8.
31. Centers for Disease Control. Background on antibiotic resistance. Atlanta, Ga: Centers for Disease Control; 2004. Available at: http://www.cdc.gov/drugresistance/community. Accessed 2006 February 21.
32. Health Canada. Controlling antimicrobial resistance: an integrated action plan for Canadians. Can Commun Dis Rep 1997;23(Suppl 7):1-32.
33. Centers for Disease Control. A public health action plant to combat antimicrobial resistance. Atlanta, Ga: Centers for Disease Control; 2005. Available at: http://www.cdc.gov/drugresistance/actionplan/html/ index.htm. Accessed 2006 February 21.
34. Alliance for Prudent Use of Antibiotics. Antibiotic resistance: synthesis of recommendations by expert policy groups. Geneva, Switz: World Health Organization/CDS/CSR/DRS; 2001.
35. World Health Organization. WHO global strategy for containment of antimicrobial resistance. Geneva, Switz: WHO/CDS/CSR/DRS; 2001. Available at: http://www.who.int/csr/drugresist/ WHO_Global_Strategy_English.pdf. Accessed 2006 February 21.
36. McCaig LF, Besser RE, Hughes JM. Antimicrobial-drug prescription in ambulatory care settings, United States 1992-2000. Emerg Infect Dis 2003;9:432-7.
37. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004;39:75-80.
38. Naber KG. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother 2000;46(Suppl 1):49-52.
39. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim/ sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002;34:1061-6.
40. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9.
41. Anti-Infective Review Panel. Anti-infective guidelines for community-acquired infections. Toronto, Ont: Medication Use management Services, Guideline Clearinghouse; 2005.
42. Harding G, Chair; Damant R, Glubish D, Robinson S, Wilde E, Sherghin A, et al. The antibiotic puzzle - urinary tract infections in adults. St Albert, Alta: Barnes, Daly, Fenwick and Associates Inc, Consultants in Healthcare;1996.
43. Blondel-Hill E, Fryters S. Bugs & drugs antimicrobial pocket reference. Edmonton, Alta: Capital Health; 2001, p. 212-3.
44. Levine M, Lexchin J, Pellizzari R, editors. Drugs of choice: a formulary for general practice. 3rd ed. Ottawa, Ont: Canadian Medical Association; 1998. p. 152-3.
45. Antibiotic Subcommittee, Pharmacy and Therapeutics Committee. Guidelines for antimicrobial use. Toronto, Ont: University Health Network; 2001. p. 91.
46. Lanthier L, Guide pratique de médecine interne du Québec. 2nd ed. Three-Rivers, Que: Formed, Inc; 2002. p. 138-9.
47. Gilbert DN, Sande MA, Moellering RC Jr. The Sanford guide to antimicrobial therapy. 33rd ed. Hyde Park, Vt: Antimicrobial Therapy, Inc; 2002. p. 23.
48. Stewart J, Pilla J, Dunn L. Pilot study for appropriate anti-infective community therapy. Effect of a guideline-based strategy to optimize use of antibiotics. Can Fam Physician 2000;46:851-9.